LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
Thursday, Laboratory Corp (NYSE:A) reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.
纽交所:A股的实验室公司在2024年第二季度报告了每股收益3.94美元，比去年同期的3.42美元上升，超过了3.78美元的共识。
Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion.
营业收入同比增长6.2%至32.2亿美元，超出了31.9亿美元的共识。
The increase was due to organic revenue of 3.8%, acquisitions, and net of divestitures of 2.5%, partially offset by foreign currency translation of (0.1%).
增加是由于有机营收增长了3.8％，收购和减值后的净额为2.5％，部分抵消了货币汇率转换的（0.1％）。
The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset by a (0.7%) decrease in COVID-19 testing.
有机营收增长3.8％，其中公司有机基础业务增长了4.5％，部分抵消了COVID-19测试的下降0.7％。
Operating income for the quarter was $294.8 million, or 9.2% of revenue, compared to $266.3 million, or 8.8%, in the second quarter of 2023.
本季度运营收入为29480万美元，占营业收入的9.2％，而2023年第二季度为26630万美元，占营业收入的8.8％。
Diagnostics Laboratories revenue for the quarter was $2.52 billion, an increase of 7.9%.
诊断实验室本季度营收为25.2亿美元，增长了7.9％。
Biopharma Laboratory Services revenue increased 1.1% to $707.0 million.
生物制药实验室服务营收增长了1.1％至70700万美元。
Guidance: LabCorp cuts its 2024 adjusted EPS outlook from $14.45-$15.35 to $14.30-$14.90, compared to the consensus of $14.82.
指引：LabCorp将其2024年调整后每股收益预期从14.45-15.35美元下调到14.30-14.90美元，而共识预期为14.82美元。
The company raised the 2024 revenue growth outlook from 4.8%- 6.4% to 6.4%- 7.5%, compared to the consensus of $12.83 billion.
与共识预期的128.3亿美元相比，公司将2024年的收入增长预期从4.8％-6.4％上调至6.4％-7.5％。
William Blair writes, "At first blush, there is not much to pick at in the quarter as modest revenue upside and margin expansion above expectation should be viewed positively."
William Blair写道，“乍一看，季度里没有太多可以挑刺的地方，适度的营收增长和较高的利润率应该受到肯定。”
With expectations slightly lowered compared to last week following Quest Diagnostics Incorporated's (NYSE:DGX) report, the analyst writes the update will help Labcorp shares maintain their current multiple of around 13 times the expected 2025 EPS.
由于Quest Diagnostics Incorporated (NYSE: DGX)的报告与上周相比稍有下降，分析师写道，这次更新将帮助Labcorp股票维持目前的每股收益预期的13倍左右。
Although the reductions in profitability related to Invitae are slightly greater than anticipated, this should provide ample opportunity for Labcorp to demonstrate the long-term value of this acquisition.
尽管与预期略有不同，与Invitae相关的盈利降低应该为Labcorp提供充足的机会来展示这笔收购的长期价值。
Labcorp remains well-positioned as a reliable and predictable growth company within the healthcare sector.
Labcorp仍然是医疗保健板块内可靠和可预测的增长公司。
William Blair reiterates the Outperform rating.
William Blair重申Outperform评级。
Price Action: LH stock is up 6.10% at $228.59 at the last check on Thursday.
股票价格行动：上周四LH股票价格上涨6.10％，至每股228.59美元。
- Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales.
- Biogen第二季度盈利：超过共识，提升2024年利润预测，因为预计新药推出将抵消原有多发性硬化药品销售额下降。
Photo via Wikimedia Commons
照片通过Wikimedia Commons